CoChat

Machine learning methods, databases and tools for drug combination prediction

Wu, Lianlian, Wen, Yuqi, Leng, Dongjin, Zhang, Qinglong, Dai, Chong, Wang, Zhongming, Liu, Ziqi, Yan, Bowei, Zhang, Yixin, Wang, Jing, He, Song, Bo, Xiaochen · 2022 · Briefings in Bioinformatics
Cited by 126

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Combination therapy has shown an obvious efficacy on complex diseases and can greatly reduce the development of drug resistance. However, even with high-throughput screens, experimental methods are insufficient to explore novel drug combinations. In order to reduce the search space of drug combinations, there is an urgent need to develop more efficient computational methods to predict novel drug combinations. In recent decades, more and more machine learning (ML) algorithms have been applied to improve the predictive performance. The object of this study is to introduce and discuss the recent applications of ML methods and the widely used databases in drug combination prediction. In this study, we first describe the concept and controversy of synergism between drug combinations. Then, we investigate various publicly available data resources and tools for prediction tasks. Next, ML methods including classic ML and deep learning methods applied in drug combination prediction are introduced. Finally, we summarize the challenges to ML methods in prediction tasks and provide a discussion on future work.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbab355

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 128

  1. Jia, 2009, Mechanisms of drug combinations: interaction and network perspectives, Nat Rev Drug Discov, 8, 111, 10.1038/nrd2683 · DOI · Paper page
  2. Lopez, 2017, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nature Nat Rev Clin Oncol, 14, 57, 10.1038/nrclinonc.2016.96 · DOI · Paper page
  3. Pang, 2014, Combinatorial therapy discovery using mixed integer linear programming, Bioinformatics, 30, 1456, 10.1093/bioinformatics/btu046 · DOI
  4. Hopkins, 2008, Network pharmacology: the next paradigm in drug discovery, Nat Chem Biol, 4, 682, 10.1038/nchembio.118 · DOI · Paper page
  5. Ramsay, 2018, A perspective on multi-target drug discovery and design for complex diseases, Clin Transl Med, 7, 3, 10.1186/s40169-017-0181-2 · DOI · Paper page
  6. Sheng, 2017, Advances in computational approaches in identifying synergistic drug combinations, Brief Bioinform, 19, 1172
  7. Narayan, 2020, A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities, Nat Commun, 11, 2935, 10.1038/s41467-020-16735-2 · DOI
  8. Housman, 2014, Drug resistance in cancer: an overview, Cancer, 6, 1769, 10.3390/cancers6031769 · DOI · Paper page
  9. Chang, 2001, Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters, Science, 293, 1793, 10.1126/science.293.5536.1793 · DOI · Paper page
  10. Toy, 2013, ESR1 ligand-binding domain mutations in hormone-resistant breast cancer, Nat Genet, 45, 1439, 10.1038/ng.2822 · DOI · Paper page
  11. Lovly, 2014, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies, Clin Cancer Res, 20, 2249, 10.1158/1078-0432.CCR-13-1610 · DOI · Paper page
  12. Madani Tonekaboni, 2018, Predictive approaches for drug combination discovery in cancer, Brief Bioinform, 19, 263, 10.1093/bib/bbw104 · DOI · Paper page
  13. Ianevski, 2019, Prediction of drug combination effects with a minimal set of experiments, Nat Mach Intell, 1, 568, 10.1038/s42256-019-0122-4 · DOI · Paper page
  14. Preuer, 2018, Deep synergy: predicting anti-cancer drug synergy with deep learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
  15. Leh, Aacute, R J, 2, 2009, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat Biotechnol, 27, 659, 10.1038/nbt.1549 · DOI · Paper page
  16. Tan, 2012, Systematic identification of synergistic drug pairs targeting HIV, Nat Biotechnol, 30, 1125, 10.1038/nbt.2391 · DOI · Paper page
  17. Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, 10.1371/journal.pcbi.1002323 · DOI · Paper page
  18. Bleicher, 2003, Hit and lead generation: beyond high-throughput screening, Nat Rev Drug Discov, 2, 369, 10.1038/nrd1086 · DOI · Paper page
  19. Morris, 2016, Systematic analysis of quantitative logic model ensembles predicts drug combination effects on cell signaling networks, CPT Pharmacometrics Syst Pharmacol, 5, 544, 10.1002/psp4.12104 · DOI
  20. Feala, 2010, Systems approaches and algorithms for discovery of combinatorial therapies, Wiley Interdiscip Rev Syst Biol Med, 2, 181, 10.1002/wsbm.51 · DOI · Paper page
  21. Sun, 2016, Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination, Oncotarget, 7, 63995, 10.18632/oncotarget.11745 · DOI · Paper page
  22. Lee, 2012, CDA: combinatorial drug discovery using transcriptional response modules, Plos One, 7, 10.1371/journal.pone.0042573 · DOI
  23. Zinner, 2009, Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells, Mol Cancer Ther, 8, 521, 10.1158/1535-7163.MCT-08-0937 · DOI
  24. Talevi, 2020, Machine learning in drug discovery and development part 1: a primer, CPT Pharmacometrics Syst Pharmacol, 9, 129, 10.1002/psp4.12491 · DOI · Paper page
  25. Tsigelny, 2019, Artificial intelligence in drug combination therapy, Brief Bioinform, 20, 1434, 10.1093/bib/bby004 · DOI · Paper page
  26. Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat Commun, 10, 10.1038/s41467-019-09799-2 · DOI · Paper page
  27. Sidorov, 2019, Predicting synergism of cancer drug combinations using NCI-ALMANAC data, Front Chem, 7, 10.3389/fchem.2019.00509 · DOI · Paper page
  28. Huang, 2014, Drug combo ranker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
  29. Sun, 2015, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer, Nat Commun, 6, 10.1038/ncomms9481 · DOI · Paper page
  30. Chen, 2016, NLLSS: predicting synergistic drug combinations based on semi-supervised learning, PLoS Comput Biol, 12, 10.1371/journal.pcbi.1004975 · DOI · Paper page
  31. Zagidullin, 2019, Drug comb: an integrative cancer drug combination data portal, Nucleic Acids Res, 47, W43, 10.1093/nar/gkz337 · DOI · Paper page
  32. Tang, 2015, What is synergy? The Saariselka agreement revisited, Front Pharmacol, 6, 10.3389/fphar.2015.00181 · DOI · Paper page
  33. Chou, 2008, Preclinical versus clinical drug combination studies, Leuk Lymphoma, 49, 2059, 10.1080/10428190802353591 · DOI · Paper page
  34. Loewe, 1953, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, 3, 285
  35. Shafer, 2008, Additivity versus synergy: a theoretical analysis of implications for anesthetic mechanisms, Anesth Anal, 107, 507, 10.1213/ane.0b013e31817b7140 · DOI
  36. Laskey, 2014, A mechanistic theory to explain the efficacy of antiretroviral therapy, Nat Rev Microbiol, 12, 772, 10.1038/nrmicro3351 · DOI
  37. Chevereau, 2015, Systematic discovery of drug interaction mechanisms, Mol Syst Biol, 11, 807, 10.15252/msb.20156098 · DOI · Paper page
  38. Tallarida, 2006, An overview of drug combination analysis with isobolograms, J Pharmacol Exp Ther, 319, 1, 10.1124/jpet.106.104117 · DOI · Paper page
  39. Greco, 1995, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, 47, 331
  40. Chou, 1983, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X · DOI · Paper page
  41. Zheng, 2021, Drug comb update: a more comprehensive drug sensitivity data repository and analysis portal, Nucleic Acids Res, 1
  42. Hancock, 2020, CatBoost for big data: an interdisciplinary review, J Big Data, 7, 94, 10.1186/s40537-020-00369-8 · DOI · Paper page
  43. Liu, 2019, DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy, Nucleic Acids Res, 48, D871
  44. Giordano, 2008, From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage, Curr Med Chem, 15, 422, 10.2174/092986708783503212 · DOI · Paper page
  45. Haibe-Kains, 2020, SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology, Nucleic Acids Res, 48, W494, 10.1093/nar/gkaa421 · DOI
  46. Chen, 2014, ASDCD: antifungal synergistic drug combination database, PLoS One, 9, 10.1371/journal.pone.0086499 · DOI · Paper page
  47. Liu, 2010, DCDB: drug combination database, Bioinformatics, 26, 587, 10.1093/bioinformatics/btp697 · DOI · Paper page
  48. Liu, 2014, DCDB 2.0: a major update of the drug combination database, Database, 2014, 10.1093/database/bau124 · DOI
  49. Zhu, 2018, Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics, Nucleic Acids Res, 46, D1121, 10.1093/nar/gkx1076 · DOI · Paper page
  50. Masoudi-Sobhanzadeh, 2019, DrugR+: a comprehensive relational database for drug repurposing, combination therapy, and replacement therapy, Comput Biol Med, 109, 254, 10.1016/j.compbiomed.2019.05.006 · DOI · Paper page
  51. He, 1711, Methods for high-throughput drug combination screening and synergy scoring, Methods Mol Biol, 2018, 351
  52. Ianevski, 2017, SynergyFinder: a web application for analyzing drug combination dose–response matrix data, Bioinformatics, 33, 2413, 10.1093/bioinformatics/btx162 · DOI · Paper page
  53. Aittokallio, 2020, SynergyFinder 2.0: visual analytics of multi-drug combination synergies, Nucleic Acids Res, 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
  54. Wooten, 2021, Synergy: a python library for calculating, analyzing and visualizing drug combination synergy, Bioinformatics, 37, 1473, 10.1093/bioinformatics/btaa826 · DOI · Paper page
  55. Chou, 2007, The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies, Cancer Res, 67, 637
  56. Di Veroli, 2016, Combenefit: an interactive platform for the analysis and visualization of drug combinations, Bioinformatics, 32, 2866, 10.1093/bioinformatics/btw230 · DOI · Paper page
  57. Noble, 2006, What is a support vector machine?, Nat Biotechnol, 24, 1565, 10.1038/nbt1206-1565 · DOI · Paper page
  58. Safavian, 1991, A survey of decision tree classifier methodology, IEEE Trans Syst Man Cybern, 21, 660, 10.1109/21.97458 · DOI · Paper page
  59. Schmidhuber, 2015, Deep learning in neural networks: an overview, Neural Netw, 61, 85, 10.1016/j.neunet.2014.09.003 · DOI · Paper page
  60. Yuming, 2015, Deep belief networks and deep learning, 10.1109/ICAIOT.2015.7111524 · DOI · Paper page
  61. Kramer, 1991, Nonlinear principal component analysis using autoassociative neural networks, AIChE J, 37, 233, 10.1002/aic.690370209 · DOI · Paper page
  62. Janizek, 2018, Explainable machine learning prediction of synergistic drug combinations for precision cancer medicine, bioRxiv
  63. Gayvert, 2017, A computational approach for identifying synergistic drug combinations, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005308 · DOI · Paper page
  64. Xu, 2017, PDC-SGB: prediction of effective drug combinations using a stochastic gradient boosting algorithm, J Theor Biol, 417, 1, 10.1016/j.jtbi.2017.01.019 · DOI
  65. Rifaioglu, 2019, Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases, Brief Bioinform, 20, 1878, 10.1093/bib/bby061 · DOI · Paper page
  66. Jiao, 2016, Performance measures in evaluating machine learning based bioinformatics predictors for classifications, Quant Biol, 4, 320, 10.1007/s40484-016-0081-2 · DOI · Paper page
  67. Rendle, 2010, Factorization machines, 10.1109/ICDM.2010.127 · DOI · Paper page
  68. Friedman, 2002, Stochastic gradient boosting, Comput Stat Data Anal, 38, 367, 10.1016/S0167-9473(01)00065-2 · DOI · Paper page
  69. Webb, 2010, Naïve Bayes. Encyclopedia of Machine Learning, 713
  70. Wright, 1995, Logistic Regression. Reading and Understanding Multivariate Statistics, 217
  71. Sun, 2014, A hadoop-based method to predict potential effective drug combination, Biomed Res Int, 2014, 196858, 10.1155/2014/196858 · DOI
  72. Li, 2020, A machine learning method for drug combination prediction, Front Genet, 11, 1000, 10.3389/fgene.2020.01000 · DOI
  73. Pivetta, 2013, Development and validation of a general approach to predict and quantify the synergism of anti-cancer drugs using experimental design and artificial neural networks, Talanta, 115, 84, 10.1016/j.talanta.2013.04.031 · DOI
  74. Julkunen, 2020, Leveraging multiway interactions for systematic prediction of pre-clinical drug combination effects, Nat Commun, 11, 10.1038/s41467-020-19950-z · DOI · Paper page
  75. Polikar, 2006, Ensemble based systems in decision making, IEEE Circuits Syst Mag, 6, 21, 10.1109/MCAS.2006.1688199 · DOI · Paper page
  76. Breiman, 1996, Bagging predictors, Machine Learning, 24, 123, 10.1007/BF00058655 · DOI · Paper page
  77. Wildenhain, 2015, Prediction of synergism from chemical-genetic interactions by machine learning, Cell Syst, 1, 383, 10.1016/j.cels.2015.12.003 · DOI · Paper page
  78. Chen, 2013, Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways, Biomed Res Int, 2013, 1, 10.1155/2013/839761 · DOI
  79. Kalantarmotamedi, 2018, A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria, Malar J, 17, 160, 10.1186/s12936-018-2294-5 · DOI
  80. Li, 2017, Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles, Artif Intell Med, 83, 35, 10.1016/j.artmed.2017.05.008 · DOI
  81. Ma, 2019, Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against tuberculosis, MBio, 10, 10.1128/mBio.02627-19 · DOI
  82. He, 2018, Patient-customized drug combination prediction and testing for T-cell prolymphocytic leukemia patients, Cancer Res, 78, 2407, 10.1158/0008-5472.CAN-17-3644 · DOI
  83. Lo, 2019, Machine learning with statistical imputation for predicting drug approval, Harvard Data Sci Rev, 1
  84. Degenhardt, 2019, Evaluation of variable selection methods for random forests and omics data sets, Brief Bioinform, 20, 492, 10.1093/bib/bbx124 · DOI · Paper page
  85. Verikas, 2016, Electromyographic patterns during golf swing: activation sequence profiling and prediction of shot effectiveness, Sensors, 16, 10.3390/s16040592 · DOI
  86. Zhang, 2017, Predicting potential drug-drug interactions by integrating chemical, biological, phenotypic and network data, BMC Bioinformatics, 18, 18, 10.1186/s12859-016-1415-9 · DOI · Paper page
  87. Tang, 2020, Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19, Front Immunol, 11, 603615, 10.3389/fimmu.2020.603615 · DOI
  88. Shi, 2019, Predicting combinative drug pairs via multiple classifier system with positive samples only, Comput Methods Programs Biomed, 168, 1, 10.1016/j.cmpb.2018.11.002 · DOI
  89. Baptista, 2021, Deep learning for drug response prediction in cancer, Brief Bioinform, 22, 360, 10.1093/bib/bbz171 · DOI · Paper page
  90. Muzio, 2021, Biological network analysis with deep learning, Brief Bioinform, 22, 1515, 10.1093/bib/bbaa257 · DOI · Paper page
  91. Kuru, 2021, MatchMaker: a deep learning framework for drug synergy prediction, IEEE/ACM Trans Comput Biol Bioinform, 1, 10.1109/TCBB.2021.3086702 · DOI · Paper page
  92. Larochelle, 2012, Learning algorithms for the classification restricted Boltzmann machine, J Mach Learn Res, 13, 643
  93. Hinton, 2006, A fast learning algorithm for deep belief nets, Neural Comput, 18, 1527, 10.1162/neco.2006.18.7.1527 · DOI · Paper page
  94. Chen, 2018, Predict effective drug combination by deep belief network and ontology fingerprints, J Biomed Inform, 85, 149, 10.1016/j.jbi.2018.07.024 · DOI · Paper page
  95. Zhang, 2021, Synergistic drug combination prediction by integrating multiomics data in deep learning models, Methods Mol Biol, 2194, 223, 10.1007/978-1-0716-0849-4_12 · DOI · Paper page
  96. Kipf, 2016, Semi-Supervised Classification with Graph Convolutional Networks
  97. Jiang, 2020, Deep graph embedding for prioritizing synergistic anticancer drug combinations, Comput Struct Biotechnol J, 18, 427, 10.1016/j.csbj.2020.02.006 · DOI · Paper page
  98. Boven, 2005, Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule, Br J Cancer, 92, 1636, 10.1038/sj.bjc.6602553 · doi:10.1038/sj.bjc.6602553
  99. Malyutina, 2019, Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer, PLoS Comput Biol, 15, 10.1371/journal.pcbi.1006752 · DOI · Paper page
  100. Richards, 2020, Drug antagonism and single-agent dominance result from differences in death kinetics, Nat Chem Biol, 16, 791, 10.1038/s41589-020-0510-4 · DOI
  101. Guan, 2019, Anticancer drug response prediction in cell lines using weighted graph regularized matrix factorization, Mol Ther Nucleic Acids, 17, 164, 10.1016/j.omtn.2019.05.017 · DOI
  102. Liu, 2018, Anti-cancer drug response prediction using neighbor-based collaborative filtering with global effect removal, Mol Ther - Nucleic Acids, 13, 303, 10.1016/j.omtn.2018.09.011 · DOI
  103. Yang, 2008, Finding multiple target optimal intervention in disease-related molecular network, Mol Syst Biol, 4, 228, 10.1038/msb.2008.60 · DOI · Paper page
  104. Cheng, 2019, Network-based prediction of drug combinations, Nat Commun, 10, 1197, 10.1038/s41467-019-09186-x · DOI · Paper page
  105. Tang, 2013, Target inhibition networks: predicting selective combinations of Druggable targets to block cancer survival pathways, PLoS Comput Biol, 9, 10.1371/journal.pcbi.1003226 · DOI · Paper page
  106. Hu, 2019, Prediction of synergistic drug combinations by learning from deep representations of multiple networks, Stud Health Technol Inform, 264, 1482
  107. Huang, 2014, Systematic prediction of drug combinations based on clinical side-effects, Sci Rep, 4, 7160, 10.1038/srep07160 · DOI · Paper page
  108. Shi, 2017, Predicting combinative drug pairs towards realistic screening via integrating heterogeneous features, BMC Bioinformatics, 18, 409, 10.1186/s12859-017-1818-2 · DOI
  109. Ji, 2019, Five-feature model for developing the classifier for synergistic vs. antagonistic drug combinations built by XGBoost, Front Genet, 10, 600, 10.3389/fgene.2019.00600 · DOI
  110. Liu, 2019, Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network, BMC Bioinformatics, 20, 645, 10.1186/s12859-019-3288-1 · DOI · Paper page
  111. Zhang, 2019, Synergistic drug combinations prediction by integrating pharmacological data, Synth Syst Biotechnol, 4, 67, 10.1016/j.synbio.2018.10.002 · DOI
  112. Szklarczyk, 2016, STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data, Nucleic Acids Res, 44, D380, 10.1093/nar/gkv1277 · DOI · Paper page
  113. Kanehisa, 2006, From genomics to chemical genomics: new developments in KEGG, Nucleic Acids Res, 34, D354, 10.1093/nar/gkj102 · DOI · Paper page
  114. Kanehisa, 2008, KEGG for linking genomes to life and the environment, Nucleic Acids Res, 36, D480
  115. Kuhn, 2016, The SIDER database of drugs and side effects, Nucleic Acids Res, 44, D1075, 10.1093/nar/gkv1075 · DOI · Paper page
  116. Kim, 2019, PubChem 2019 update: improved access to chemical data, Nucleic Acids Res, 47, D1102, 10.1093/nar/gky1033 · DOI · Paper page
  117. Oughtred, 2019, The BioGRID interaction database: 2019 update, Nucleic Acids Res, 47, D529, 10.1093/nar/gky1079 · DOI · Paper page
  118. Keshava Prasad, 2009, Human protein reference database--2009 update, Nucleic Acids Res, 37, D767, 10.1093/nar/gkn892 · DOI · Paper page
  119. Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res, 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
  120. Tang, 2018, Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions, Cell Chem Biol, 25, 224, 10.1016/j.chembiol.2017.11.009 · DOI · Paper page
  121. Berenstein, 2020, TDR targets 6: driving drug discovery for human pathogens through intensive chemogenomic data integration, Nucleic Acids Res, 48, D992
  122. Pawson, 2014, The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands, Nucleic Acids Res, 42, D1098, 10.1093/nar/gkt1143 · DOI · Paper page
  123. Kumar, 2013, CancerDR: cancer drug resistance database, Sci Rep, 3, 1445, 10.1038/srep01445 · DOI · Paper page
  124. Liu, 2007, BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities, Nucleic Acids Res, 35, D198, 10.1093/nar/gkl999 · DOI · Paper page
  125. He, 2015, TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples, Bioinformatics, 31, 1866, 10.1093/bioinformatics/btv067 · DOI
  126. Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 10.1093/bioinformatics/btv080 · DOI · Paper page
  127. Held, 2013, Genotype-selective combination therapies for melanoma identified by high-throughput drug screening, Cancer Discov, 3, 52, 10.1158/2159-8290.CD-12-0408 · DOI · Paper page
  128. Mott, 2015, High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations, Sci Rep, 5, 13891, 10.1038/srep13891 · DOI · Paper page

Cited by

See all 126

Metadata

Authors
Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., He, S., & Bo, X.
Venue
Briefings in Bioinformatics
Published
2021-09-02
Volume
23
Issue
1
ISSN
  • 1467-5463
  • 1477-4054
Cited by
126
References
34
Language
en
Funders
National Natural Science Foundation of China (62103436)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Machine learning methods, databases and tools for drug combination prediction. https://app.cochat.ai/papers/10.1093/bib/bbab355
The paper
Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., He, S., & Bo, X. (2022). Machine learning methods, databases and tools for drug combination prediction. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbab355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.